Your browser doesn't support javascript.
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection.
Khan, Khadija; Karim, Farina; Ganga, Yashica; Bernstein, Mallory; Jule, Zesuliwe; Reedoy, Kajal; Cele, Sandile; Lustig, Gila; Amoako, Daniel; Wolter, Nicole; Samsunder, Natasha; Sivro, Aida; San, James Emmanuel; Giandhari, Jennifer; Tegally, Houriiyah; Pillay, Sureshnee; Naidoo, Yeshnee; Mazibuko, Matilda; Miya, Yoliswa; Ngcobo, Nokuthula; Manickchund, Nithendra; Magula, Nombulelo; Karim, Quarraisha Abdool; von Gottberg, Anne; Abdool Karim, Salim S; Hanekom, Willem; Gosnell, Bernadett I; Lessells, Richard J; de Oliveira, Tulio; Moosa, Mahomed-Yunus S; Sigal, Alex.
  • Khan K; Africa Health Research Institute, Durban, South Africa.
  • Karim F; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Ganga Y; Africa Health Research Institute, Durban, South Africa.
  • Bernstein M; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Jule Z; Africa Health Research Institute, Durban, South Africa.
  • Reedoy K; Africa Health Research Institute, Durban, South Africa.
  • Cele S; Africa Health Research Institute, Durban, South Africa.
  • Lustig G; Africa Health Research Institute, Durban, South Africa.
  • Amoako D; Africa Health Research Institute, Durban, South Africa.
  • Wolter N; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Samsunder N; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Sivro A; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • San JE; School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Giandhari J; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Tegally H; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Pillay S; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Naidoo Y; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Mazibuko M; Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa.
  • Miya Y; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Ngcobo N; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Manickchund N; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Magula N; Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
  • Karim QA; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • von Gottberg A; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Abdool Karim SS; Africa Health Research Institute, Durban, South Africa.
  • Hanekom W; Africa Health Research Institute, Durban, South Africa.
  • Gosnell BI; Africa Health Research Institute, Durban, South Africa.
  • Lessells RJ; Division of Internal Medicine, Nelson R. Mandela School of Medicine, University of Kwa-Zulu Natal, Durban, South Africa.
  • de Oliveira T; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Moosa MS; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Sigal A; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Nat Commun ; 13(1): 4686, 2022 08 10.
Article in English | MEDLINE | ID: covidwho-1984389
ABSTRACT
SARS-CoV-2 Omicron (B.1.1.529) BA.4 and BA.5 sub-lineages, first detected in South Africa, have changes relative to Omicron BA.1 including substitutions in the spike receptor binding domain. Here we isolated live BA.4 and BA.5 viruses and measured BA.4/BA.5 neutralization elicited by BA.1 infection either in the absence or presence of previous vaccination as well as from vaccination without BA.1 infection. In BA.1-infected unvaccinated individuals, neutralization relative to BA.1 declines 7.6-fold for BA.4 and 7.5-fold for BA.5. In vaccinated individuals with subsequent BA.1 infection, neutralization relative to BA.1 decreases 3.2-fold for BA.4 and 2.6-fold for BA.5. The fold-drop versus ancestral virus neutralization in this group is 4.0-fold for BA.1, 12.9-fold for BA.4, and 10.3-fold for BA.5. In contrast, BA.4/BA.5 escape is similar to BA.1 in the absence of BA.1 elicited immunity fold-drop relative to ancestral virus neutralization is 19.8-fold for BA.1, 19.6-fold for BA.4, and 20.9-fold for BA.5. These results show considerable escape of BA.4/BA.5 from BA.1 elicited immunity which is moderated with vaccination and may indicate that BA.4/BA.5 may have the strongest selective advantage in evading neutralization relative to BA.1 in unvaccinated, BA.1 infected individuals.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-32396-9

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-32396-9